Skip to main content

Animations

MJFF Publications

3531 - 3540 of 6412 Results
Title
Year
  • Year
  • 2022
  • 2015
  • 2012
  • 2017
  • 2022
  • 2019
  • 2017
  • 2017
  • 2025
  • 2021
  • Summary Details
    OPEN
    Title: LRRK2 dynamics analysis identifies allosteric control of the crosstalk between its catalytic domains
    Journal Name: PLOS Biology
    Publisher: Public Library of Science (PLoS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1371/journal.pbio.3001427
    Citation Count: 25
  • Summary Details
    OPEN
    Title: Fidelity of frequency and phase entrainment of circuit-level spike activity during DBS
    Journal Name: Journal of Neurophysiology
    Publisher: American Physiological Society
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1152/jn.00259.2015
    Citation Count: 47
  • Summary Details
    OPEN
    Title: GSK2578215A; A potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor
    Journal Name: Bioorganic & Medicinal Chemistry Letters
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.bmcl.2012.06.104
    Citation Count: 149
  • Summary Details
    OPEN
    Title: Heritability of hippocampal subfield volumes using a twin and non-twin siblings design
    Journal Name: Human Brain Mapping
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/hbm.23654
    Citation Count: 29
  • Summary Details
    OPEN
    Title: Longitudinal Trajectories of Memory Performance in Patients with Early-Stage Breast Cancer
    Journal Name: Journal of Oncology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1155/2022/5899728
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Development of a Disease Progression Model for Leucine‐Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial Designs
    Journal Name: Clinical Pharmacology & Therapeutics
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/cpt.1634
    Citation Count: 18
  • Summary Details
    OPEN
    Title: A sensitive assay reveals structural requirements for α-synuclein fibril growth
    Journal Name: Journal of Biological Chemistry
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1074/jbc.m116.767053
    Citation Count: 25
  • Summary Details
    OPEN
    Title: Evidence for an Additive Neurorestorative Effect of Simultaneously Administered CDNF and GDNF in Hemiparkinsonian Rats: Implications for Different Mechanism of Action
    Journal Name: eneuro
    Publisher: Society for Neuroscience
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1523/eneuro.0117-16.2017
    Citation Count: 52
  • Summary Details
    OPEN
    Title: Investigating the ageing-Parkinson’s disease nexus: standardisation of in vitro models and techniques by the PD-AGE network
    Journal Name: npj Parkinson's Disease
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41531-025-01137-2
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Allosteric Inhibition of Parkinson’s-Linked LRRK2 by Constrained Peptides
    Journal Name: ACS Chemical Biology
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1021/acschembio.1c00487
    Citation Count: 36
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.